Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Blood (2024) 144 (Supplement 1): 1332.

https://doi.org/10.1182/blood-2024-194024

Published: 2024

Journal Articles

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2023-185857

Published: 2023

Journal Articles

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro M. Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin G. Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2023) 141 (5): 534–549.

https://doi.org/10.1182/blood.2022018221

Published: 2023

Includes: Supplemental data

Journal Articles

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, Sophia C. Korotev, Carmelo Gurnari, June Takeda, Yukihide Momozawa, Steve Best, Pramila Krishnamurthy, Tetsuichi Yoshizato, Yoshiko Atsuta, Yusuke Shiozawa, Yuka Iijima-Yamashita, Kenichi Yoshida, Yuichi Shiraishi, Yasunobu Nagata, Nobuyuki Kakiuchi, Makoto Onizuka, Kenichi Chiba, Hiroko Tanaka, Ayana Kon, Yotaro Ochi, Masahiro Marshall Nakagawa, Rurika Okuda, Takuto Mori, Akinori Yoda, Hidehiro Itonaga, Yasushi Miyazaki, Masashi Sanada, Takayuki Ishikawa, Shigeru Chiba, Hisashi Tsurumi, Senji Kasahara, Carsten Müller-Tidow, Akifumi Takaori-Kondo, Kazuma Ohyashiki, Toru Kiguchi, Fumihiko Matsuda, Joop H. Jansen, Chantana Polprasert, Piers Blombery, Yoichiro Kamatani, Satoru Miyano, Luca Malcovati, Torsten Haferlach, Michiaki Kubo, Mario Cazzola, Austin Kulasekararaj, Lucy A. Godley, Jaroslaw P. Maciejewski, Seishi Ogawa

Blood (2022) 140 (Supplement 1): 208–210.

https://doi.org/10.1182/blood-2022-158851

Published: 2022

Journal Articles

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Blood (2022) 140 (Supplement 1): 6902–6904.

https://doi.org/10.1182/blood-2022-168213

Published: 2022

Journal Articles

Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2021-149556

Published: 2021

Journal Articles

EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia

Blood (2021) 138 (Supplement 1): 610.

https://doi.org/10.1182/blood-2021-152800

Published: 2021

Journal Articles

Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms

Hideki Makishima, MD PhD, Yasuhito Nannya, MD PhD, June Takeda, MD, Yukihide Momozawa, DVM,PhD, Ryunosuke Saiki, MD, Tetsuichi Yoshizato, MD PhD, Yoshiko Atsuta, MD PhD, Yuka Iijima-Yamashita, Kenichi Yoshida, MD PhD, Yuichi Shiraishi, PhD, Yasunobu Nagata, MD PhD, Yusuke Shiozawa, MD PhD, Makoto Onizuka, MD PhD, Kenichi Chiba, Hiroko Tanaka, Nobuyuki Kakiuchi, MD, Yotaro Ochi, MD, Hiroo Ueno, MD PhD, Hidehiro Itonaga, MD PhD, Yoshinobu Kanda, MD PhD, Masashi Sanada, MD, Ayana Kon, MD PhD, Yasushi Miyazaki, MD PhD, Keizo Horibe, MD PhD, Maria Creignou, Magnus Tobiasson, MD, Hisashi Tsurumi, MD PhD, Senji Kasahara, MD PhD, Chantana Polprasert, MD, Eva Hellstrom Lindberg, MD PhD, Akifumi Kondo Takaori, MD PhD, Toru Kiguchi, MD PhD, Mario Cazzola, MD, Fumihiko Matsuda, MD PhD, Kazuma Ohyashiki, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD, Yoichiro Kamatani, MDPhD, Michiaki Kubo, MDPhD, Satoru Miyano, PhD, Seishi Ogawa, MD PhD

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-140174

Published: 2020

Journal Articles

Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139082

Published: 2020

Journal Articles

Molecular Characteristics That Predict Response to Azacitidine Therapy

Blood (2019) 134 (Supplement_1): 4246.

https://doi.org/10.1182/blood-2019-129420

Published: 2019

Journal Articles

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 4249.

https://doi.org/10.1182/blood-2018-99-114030

Published: 2018

Journal Articles

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Yuko Tanaka, Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yoshikazu Ito, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2018-99-114750

Published: 2018

Journal Articles

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

Sho Kubota, PhD, Kenji Tokunaga, MD, Tomohiro Umezu, PhD, Takako Yokomizo, PhD, Motohiko Oshima, PhD, Eisaku Iwanaga, MD PhD, Norio Asou, MDPhD, Atsushi Iwama, MD PhD, Kazuma Ohyashiki, MD PhD, Motomi Osato, MD, PhD, Goro Sashida, MD PhD

Blood (2018) 132 (Supplement 1): 761.

https://doi.org/10.1182/blood-2018-99-110333

Published: 2018

Journal Articles

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Katagiri Seiichiro, MD PhD, Kenko Azuma, PhD, Yuu Saitoh, MD, Seiichiro Yoshizawa, MD PhD, Daigo Akahane, MD PhD, Hiroaki Fujimoto, MD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko.H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5525.

https://doi.org/10.1182/blood-2018-99-113317

Published: 2018

Journal Articles

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Blood (2017) 130 (Supplement 1): 5432.

https://doi.org/10.1182/blood.V130.Suppl_1.5432.5432

Published: 2017

Journal Articles

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 3828.

https://doi.org/10.1182/blood.V130.Suppl_1.3828.3828

Published: 2017

Journal Articles

Molecular Signatures That Predict Response to Azacitidine Treatment for Myelodysplastic Syndromes

Blood (2017) 130 (Supplement 1): 4182.

https://doi.org/10.1182/blood.V130.Suppl_1.4182.4182

Published: 2017

Journal Articles

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

Michinori Ogura, MD PhD, Ken Ohmachi, MD, Ritsuro Suzuki, MD PhD, Yoshiko Atsuta, MD PhD, Tatsuya Ito, MD, Kazuma Ohyashiki, MD, Shingo Yano, MD PhD, Michihiro Hidaka, MD PhD, Kiyoshi Ando, MD PhD, Noriko Fukuhara, MD PhD, Yoshihisa Morishita, MD PhD, Takayo Suzuki, MD PhD, Kunihiro Tsukasaki, MD PhD, Naoki Kobayashi, MD PhD, Kenji Tsukamoto, MD, Yukiyasu Ozawa, MD PhD, Tomomitsu Hotta, MD PhD, Tomohiro Kinoshita, MD PhD

Blood (2017) 130 (Supplement 1): 2789.

https://doi.org/10.1182/blood.V130.Suppl_1.2789.2789

Published: 2017

Journal Articles

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1582.

https://doi.org/10.1182/blood.V130.Suppl_1.1582.1582

Published: 2017

Journal Articles

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 5241.

https://doi.org/10.1182/blood.V130.Suppl_1.5241.5241

Published: 2017

NARROW

A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41 -Mutant Myeloid Neoplasia

Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms

EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia

Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms

Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.

Molecular Characteristics That Predict Response to Azacitidine Therapy

Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Aurora A Kinase As a Promising Therapeutic Target in Philadelphia Chromosome Positive Leukemia Cells

Molecular Signatures That Predict Response to Azacitidine Treatment for Myelodysplastic Syndromes

A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG)

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Peroxisome Proliferator-Activated Receptors: Targets for the Treatment of Philadelphia Chromosome-Positive Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only